New Delhi, April 3 -- US President Donald Trump's decision to impose a 100 per cent tariff on patented pharmaceutical imports--citing national security and supply chain risks following a Section 232 probe--is expected to have a mixed impact on India.

Crucially for India, the proclamation clarifies that generic drugs--a segment in which Indian firms dominate globally--are exempt "at this time," adding that such products "shall not be subject to Section 232 tariffs."

For India, the impact is likely to be mixed. In the near term, the exclusion of generics offers a buffer, ensuring continuity in exports of low-cost medicines that form the backbone of India's pharmaceutical trade with the US. Indian drugmakers, which command a significant sh...